Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.
Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.
Term
Q3 2026
“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”
Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics
“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”
Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics